Cited by

• Patient Characteristics, Early Outcomes, and Implementation Lessons of Cervical Cancer Treatment Services in Rural Rwanda.

  Park PH, Davey S, Fehr AE, Butonzi J, Shyirambere C, Hategekimana V, Bigirimana JB, Borg R, Uwizeye R, Tapela N, Shulman LN, Randall T, Mpanumusingo E, Mpunga T. Park PH, et al. J Glob Oncol. 2018 Dec;4:1-11. doi: 10.1200/JGO.18.00120. J Glob Oncol. 2018. PMID: 30582433 Free PMC article.
• Unveiling the RKIP and EGFR Inverse Relationship in Solid Tumors: A Case Study in Cervical Cancer.

  Cardoso-Carneiro D, Pinheiro J, Fontão P, Nogueira R, Gabriela-Freitas M, Raquel-Cunha A, Mendes A, Longatto-Filho A, Marques F, Moreira MAR, Reis RM, Martinho O. Cardoso-Carneiro D, et al. Cancers (Basel). 2024 Jun 10;16(12):2182. doi: 10.3390/cancers16122182. Cancers (Basel). 2024. PMID: 38927888 Free PMC article.
• What is the evidence for the clinical value of SBRT in cancer of the cervix?

  Yanez L, Ciudad AM, Mehta MP, Marsiglia H. Yanez L, et al. Rep Pract Oncol Radiother. 2018 Nov-Dec;23(6):574-579. doi: 10.1016/j.rpor.2018.08.005. Epub 2018 Oct 9. Rep Pract Oncol Radiother. 2018. PMID: 30534021 Free PMC article. Review.
• Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors.

  Yan DD, Tang Q, Chen JH, Tu YQ, Lv XJ. Yan DD, et al. Cancer Manag Res. 2019 Jun 13;11:5473-5480. doi: 10.2147/CMAR.S203059. eCollection 2019. Cancer Manag Res. 2019. PMID: 31354353 Free PMC article.
• Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis.

  Qi L, Li N, Lin A, Wang X, Cong J. Qi L, et al. Front Oncol. 2022 Aug 10;12:910486. doi: 10.3389/fonc.2022.910486. eCollection 2022. Front Oncol. 2022. PMID: 36033480 Free PMC article.